Manish Neupane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manish Neupane has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Alison B. Shupp
5 shared publications- Daniel P. Silver
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
5 shared publications - Lebaron C. Agostini
Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
5 shared publications - Alsu Ibragimova
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
4 shared publications - Brian Curcio
Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania
4 shared publications - Colleen Donnelly
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
4 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
Supplementary Figure S2 shows the effect of MECP2 overexpression on genes that may mediate the oncogenic activity of MECP2 and their properties
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
Supplementary Figure S2 shows the effect of MECP2 overexpression on genes that may mediate the oncogenic activity of MECP2 and their properties
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
The methyl CpG-binding protein 2 (MECP2) gene has copy-number gain in a number of human cancers and functions as an oncogene through an unusual epigenetic mechanism. We explored the possibility that MECP2 might be a therapeutic target and whether its epigenetic mode of action is amenable to specific therapy. Constitutively expressed or inducible lentiviral short hairpin RNA directed at MECP2 in human triple-negative breast cancer (TNBC) cell lines with high or low level of MECP2 protein were grown as xenografts to assess oncogene addiction. We next evaluated the effect of DNA methylation inhibitors or histone deacetylase inhibitors on monolayer or soft agar growth of isogenic human mammary epithelial cells with or without MECP2 overexpression and xenograft growth of MECP2-dependent or MECP2-independent human TNBC or lung cancer cell lines. We then investigated the mechanism of MECP2-induced activation of the MAPK pathway and assessed the effect of drug treatment. Human cancer cell lines with MECP2 overexpression show MECP2 dependence, and epigenetic drugs are effective in these models. Activated RAS and other activators of the MAPK pathway caused resistance to these therapies, giving insight into their novel mode of action and demonstrating specificity. The kinase PAK3 is important for MECP2-mediated induction of the MAPK pathway, is modulated by epigenetic drugs affecting MECP2 action as expected, and may itself be a therapeutic target for MECP2-driven cancers. These preclinical studies show that tumors overexpressing MECP2 might benefit from epigenetic therapy targeting MECP2 function and demonstrate a novel mechanism of action for these drugs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
The methyl CpG-binding protein 2 (MECP2) gene has copy-number gain in a number of human cancers and functions as an oncogene through an unusual epigenetic mechanism. We explored the possibility that MECP2 might be a therapeutic target and whether its epigenetic mode of action is amenable to specific therapy. Constitutively expressed or inducible lentiviral short hairpin RNA directed at MECP2 in human triple-negative breast cancer (TNBC) cell lines with high or low level of MECP2 protein were grown as xenografts to assess oncogene addiction. We next evaluated the effect of DNA methylation inhibitors or histone deacetylase inhibitors on monolayer or soft agar growth of isogenic human mammary epithelial cells with or without MECP2 overexpression and xenograft growth of MECP2-dependent or MECP2-independent human TNBC or lung cancer cell lines. We then investigated the mechanism of MECP2-induced activation of the MAPK pathway and assessed the effect of drug treatment. Human cancer cell lines with MECP2 overexpression show MECP2 dependence, and epigenetic drugs are effective in these models. Activated RAS and other activators of the MAPK pathway caused resistance to these therapies, giving insight into their novel mode of action and demonstrating specificity. The kinase PAK3 is important for MECP2-mediated induction of the MAPK pathway, is modulated by epigenetic drugs affecting MECP2 action as expected, and may itself be a therapeutic target for MECP2-driven cancers. These preclinical studies show that tumors overexpressing MECP2 might benefit from epigenetic therapy targeting MECP2 function and demonstrate a novel mechanism of action for these drugs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
Supplementary Figure S1 shows the effect of HDAC inhibitors on MECP2 protein levels
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
Supplementary Figure S1 shows the effect of HDAC inhibitors on MECP2 protein levels
- 9 December 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (5) , 860-873
MECP2- Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
The methyl CpG-binding protein 2 (MECP2) gene has copy-number gain in a number of human cancers and functions as an oncogene through an unusual epigenetic mechanism. We explored the possibility that MECP2 might be a therapeutic target and whether its epigenetic mode of action is amenable to specific therapy. Constitutively expressed or inducible lentiviral short hairpin RNA directed at MECP2 in human triple-negative breast cancer (TNBC) cell lines with high or low level of MECP2 protein were grown as xenografts to assess oncogene addiction. We next evaluated the effect of DNA methylation inhibitors or histone deacetylase inhibitors on monolayer or soft agar growth of isogenic human mammary epithelial cells with or without MECP2 overexpression and xenograft growth of MECP2-dependent or MECP2-independent human TNBC or lung cancer cell lines. We then investigated the mechanism of MECP2-induced activation of the MAPK pathway and assessed the effect of drug treatment. Human cancer cell lines with MECP2 overexpression show MECP2 dependence, and epigenetic drugs are effective in these models. Activated RAS and other activators of the MAPK pathway caused resistance to these therapies, giving insight into their novel mode of action and demonstrating specificity. The kinase PAK3 is important for MECP2-mediated induction of the MAPK pathway, is modulated by epigenetic drugs affecting MECP2 action as expected, and may itself be a therapeutic target for MECP2-driven cancers. These preclinical studies show that tumors overexpressing MECP2 might benefit from epigenetic therapy targeting MECP2 function and demonstrate a novel mechanism of action for these drugs.
- 9 December 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (5) , 860-873
MECP2- Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
The methyl CpG-binding protein 2 (MECP2) gene has copy-number gain in a number of human cancers and functions as an oncogene through an unusual epigenetic mechanism. We explored the possibility that MECP2 might be a therapeutic target and whether its epigenetic mode of action is amenable to specific therapy. Constitutively expressed or inducible lentiviral short hairpin RNA directed at MECP2 in human triple-negative breast cancer (TNBC) cell lines with high or low level of MECP2 protein were grown as xenografts to assess oncogene addiction. We next evaluated the effect of DNA methylation inhibitors or histone deacetylase inhibitors on monolayer or soft agar growth of isogenic human mammary epithelial cells with or without MECP2 overexpression and xenograft growth of MECP2-dependent or MECP2-independent human TNBC or lung cancer cell lines. We then investigated the mechanism of MECP2-induced activation of the MAPK pathway and assessed the effect of drug treatment. Human cancer cell lines with MECP2 overexpression show MECP2 dependence, and epigenetic drugs are effective in these models. Activated RAS and other activators of the MAPK pathway caused resistance to these therapies, giving insight into their novel mode of action and demonstrating specificity. The kinase PAK3 is important for MECP2-mediated induction of the MAPK pathway, is modulated by epigenetic drugs affecting MECP2 action as expected, and may itself be a therapeutic target for MECP2-driven cancers. These preclinical studies show that tumors overexpressing MECP2 might benefit from epigenetic therapy targeting MECP2 function and demonstrate a novel mechanism of action for these drugs.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Bone is a common site of cancer metastasis, including cancers such as breast, prostate, and multiple myeloma. Disseminated tumor cells (DTC) shed from a primary tumor may travel to bone and can survive undetected for years before proliferating to form overt metastatic lesions. This period of time can be defined as metastatic latency. Once in the metastatic microenvironment, DTCs engage in intercellular communication with surrounding stromal cells, which can influence cancer cell survival, proliferation, and ultimately disease progression. The role of the surrounding tumor microenvironment in regulating DTC fate is becoming increasingly recognized. We have previously shown that in the bone microenvironment, osteoblasts are “educated” by interactions with breast cancer cells, and these “educated” osteoblasts (EO) produce soluble factors that regulate cancer cell proliferation. In this study, we provide evidence indicating that EOs produce small extracellular vesicles (sEV) that suppress breast cancer proliferation, in part through regulation of ERK1/2 signaling. In addition, using EdU-incorporation assays and propidium iodide staining we demonstrate that exposure to EO-derived sEVs decreases breast cancer cell entry to S-phase of cell cycle. We also have evidence that particular microRNAs, including miR-148a-3p, are enriched in EO-derived sEVs, and that miR-148a-3p is capable of regulating breast cancer proliferation.Implications:These findings underscore the importance of sEV-mediated communication in the earlier stages of cancer progression, and suggest that EO-derived sEVs may be one mechanism by which the bone microenvironment suppresses breast cancer cell proliferation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Bone is a common site of cancer metastasis, including cancers such as breast, prostate, and multiple myeloma. Disseminated tumor cells (DTC) shed from a primary tumor may travel to bone and can survive undetected for years before proliferating to form overt metastatic lesions. This period of time can be defined as metastatic latency. Once in the metastatic microenvironment, DTCs engage in intercellular communication with surrounding stromal cells, which can influence cancer cell survival, proliferation, and ultimately disease progression. The role of the surrounding tumor microenvironment in regulating DTC fate is becoming increasingly recognized. We have previously shown that in the bone microenvironment, osteoblasts are “educated” by interactions with breast cancer cells, and these “educated” osteoblasts (EO) produce soluble factors that regulate cancer cell proliferation. In this study, we provide evidence indicating that EOs produce small extracellular vesicles (sEV) that suppress breast cancer proliferation, in part through regulation of ERK1/2 signaling. In addition, using EdU-incorporation assays and propidium iodide staining we demonstrate that exposure to EO-derived sEVs decreases breast cancer cell entry to S-phase of cell cycle. We also have evidence that particular microRNAs, including miR-148a-3p, are enriched in EO-derived sEVs, and that miR-148a-3p is capable of regulating breast cancer proliferation.Implications:These findings underscore the importance of sEV-mediated communication in the earlier stages of cancer progression, and suggest that EO-derived sEVs may be one mechanism by which the bone microenvironment suppresses breast cancer cell proliferation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1 and 2, Supplemental Figures 1-11 from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Supplemental Table 1. Antibodies used for immunofluorescence Supplemental Table 2. Antibodies used for western blotting Supplemental Figure 1: EO-MCF7 sEVs decrease MCF7 proliferation. Supplemental Figure 2: Primary EO sEVs regulate MDA-MB-231 S-phase entry. Supplemental Figure 3: EO sEVs suppress breast cancer cell proliferation more than other EO-derived soluble factors. Supplemental Figure 4: Paclitaxel does not induce pronounced DNA damage in MDA-MB-231 cells. Supplemental Figure 5: Primary EO sEVs protect MDA-MB-231 cells from doxorubicin-induced DNA damage. Supplemental Figure 6: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 breast cancer cells. Supplemental Figure 7: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and MC3T3-E1 cells. Supplemental Figure 8: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and EO-231 cells. Supplemental Figure 9: ERK2 is a key regulator of proliferation in MDA-MB-231 cells. Supplemental Figure 10: ERK2 regulates cellular sensitivity to chemotherapy-induced cell death. Supplemental Figure 11: miR-148a-3p regulates levels of p27 but not p21.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1 and 2, Supplemental Figures 1-11 from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Supplemental Table 1. Antibodies used for immunofluorescence Supplemental Table 2. Antibodies used for western blotting Supplemental Figure 1: EO-MCF7 sEVs decrease MCF7 proliferation. Supplemental Figure 2: Primary EO sEVs regulate MDA-MB-231 S-phase entry. Supplemental Figure 3: EO sEVs suppress breast cancer cell proliferation more than other EO-derived soluble factors. Supplemental Figure 4: Paclitaxel does not induce pronounced DNA damage in MDA-MB-231 cells. Supplemental Figure 5: Primary EO sEVs protect MDA-MB-231 cells from doxorubicin-induced DNA damage. Supplemental Figure 6: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 breast cancer cells. Supplemental Figure 7: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and MC3T3-E1 cells. Supplemental Figure 8: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and EO-231 cells. Supplemental Figure 9: ERK2 is a key regulator of proliferation in MDA-MB-231 cells. Supplemental Figure 10: ERK2 regulates cellular sensitivity to chemotherapy-induced cell death. Supplemental Figure 11: miR-148a-3p regulates levels of p27 but not p21.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1 and 2, Supplemental Figures 1-11 from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Supplemental Table 1. Antibodies used for immunofluorescence Supplemental Table 2. Antibodies used for western blotting Supplemental Figure 1: EO-MCF7 sEVs decrease MCF7 proliferation. Supplemental Figure 2: Primary EO sEVs regulate MDA-MB-231 S-phase entry. Supplemental Figure 3: EO sEVs suppress breast cancer cell proliferation more than other EO-derived soluble factors. Supplemental Figure 4: Paclitaxel does not induce pronounced DNA damage in MDA-MB-231 cells. Supplemental Figure 5: Primary EO sEVs protect MDA-MB-231 cells from doxorubicin-induced DNA damage. Supplemental Figure 6: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 breast cancer cells. Supplemental Figure 7: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and MC3T3-E1 cells. Supplemental Figure 8: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and EO-231 cells. Supplemental Figure 9: ERK2 is a key regulator of proliferation in MDA-MB-231 cells. Supplemental Figure 10: ERK2 regulates cellular sensitivity to chemotherapy-induced cell death. Supplemental Figure 11: miR-148a-3p regulates levels of p27 but not p21.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1 and 2, Supplemental Figures 1-11 from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Supplemental Table 1. Antibodies used for immunofluorescence Supplemental Table 2. Antibodies used for western blotting Supplemental Figure 1: EO-MCF7 sEVs decrease MCF7 proliferation. Supplemental Figure 2: Primary EO sEVs regulate MDA-MB-231 S-phase entry. Supplemental Figure 3: EO sEVs suppress breast cancer cell proliferation more than other EO-derived soluble factors. Supplemental Figure 4: Paclitaxel does not induce pronounced DNA damage in MDA-MB-231 cells. Supplemental Figure 5: Primary EO sEVs protect MDA-MB-231 cells from doxorubicin-induced DNA damage. Supplemental Figure 6: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 breast cancer cells. Supplemental Figure 7: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and MC3T3-E1 cells. Supplemental Figure 8: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and EO-231 cells. Supplemental Figure 9: ERK2 is a key regulator of proliferation in MDA-MB-231 cells. Supplemental Figure 10: ERK2 regulates cellular sensitivity to chemotherapy-induced cell death. Supplemental Figure 11: miR-148a-3p regulates levels of p27 but not p21.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Bone is a common site of cancer metastasis, including cancers such as breast, prostate, and multiple myeloma. Disseminated tumor cells (DTC) shed from a primary tumor may travel to bone and can survive undetected for years before proliferating to form overt metastatic lesions. This period of time can be defined as metastatic latency. Once in the metastatic microenvironment, DTCs engage in intercellular communication with surrounding stromal cells, which can influence cancer cell survival, proliferation, and ultimately disease progression. The role of the surrounding tumor microenvironment in regulating DTC fate is becoming increasingly recognized. We have previously shown that in the bone microenvironment, osteoblasts are “educated” by interactions with breast cancer cells, and these “educated” osteoblasts (EO) produce soluble factors that regulate cancer cell proliferation. In this study, we provide evidence indicating that EOs produce small extracellular vesicles (sEV) that suppress breast cancer proliferation, in part through regulation of ERK1/2 signaling. In addition, using EdU-incorporation assays and propidium iodide staining we demonstrate that exposure to EO-derived sEVs decreases breast cancer cell entry to S-phase of cell cycle. We also have evidence that particular microRNAs, including miR-148a-3p, are enriched in EO-derived sEVs, and that miR-148a-3p is capable of regulating breast cancer proliferation.Implications:These findings underscore the importance of sEV-mediated communication in the earlier stages of cancer progression, and suggest that EO-derived sEVs may be one mechanism by which the bone microenvironment suppresses breast cancer cell proliferation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Bone is a common site of cancer metastasis, including cancers such as breast, prostate, and multiple myeloma. Disseminated tumor cells (DTC) shed from a primary tumor may travel to bone and can survive undetected for years before proliferating to form overt metastatic lesions. This period of time can be defined as metastatic latency. Once in the metastatic microenvironment, DTCs engage in intercellular communication with surrounding stromal cells, which can influence cancer cell survival, proliferation, and ultimately disease progression. The role of the surrounding tumor microenvironment in regulating DTC fate is becoming increasingly recognized. We have previously shown that in the bone microenvironment, osteoblasts are “educated” by interactions with breast cancer cells, and these “educated” osteoblasts (EO) produce soluble factors that regulate cancer cell proliferation. In this study, we provide evidence indicating that EOs produce small extracellular vesicles (sEV) that suppress breast cancer proliferation, in part through regulation of ERK1/2 signaling. In addition, using EdU-incorporation assays and propidium iodide staining we demonstrate that exposure to EO-derived sEVs decreases breast cancer cell entry to S-phase of cell cycle. We also have evidence that particular microRNAs, including miR-148a-3p, are enriched in EO-derived sEVs, and that miR-148a-3p is capable of regulating breast cancer proliferation.Implications:These findings underscore the importance of sEV-mediated communication in the earlier stages of cancer progression, and suggest that EO-derived sEVs may be one mechanism by which the bone microenvironment suppresses breast cancer cell proliferation.
- Open Access
- 21 May 2021
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 19 (10) , 1763-1777
Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Bone is a common site of cancer metastasis, including cancers such as breast, prostate, and multiple myeloma. Disseminated tumor cells (DTC) shed from a primary tumor may travel to bone and can survive undetected for years before proliferating to form overt metastatic lesions. This period of time can be defined as metastatic latency. Once in the metastatic microenvironment, DTCs engage in intercellular communication with surrounding stromal cells, which can influence cancer cell survival, proliferation, and ultimately disease progression. The role of the surrounding tumor microenvironment in regulating DTC fate is becoming increasingly recognized. We have previously shown that in the bone microenvironment, osteoblasts are “educated” by interactions with breast cancer cells, and these “educated” osteoblasts (EO) produce soluble factors that regulate cancer cell proliferation. In this study, we provide evidence indicating that EOs produce small extracellular vesicles (sEV) that suppress breast cancer proliferation, in part through regulation of ERK1/2 signaling. In addition, using EdU-incorporation assays and propidium iodide staining we demonstrate that exposure to EO-derived sEVs decreases breast cancer cell entry to S-phase of cell cycle. We also have evidence that particular microRNAs, including miR-148a-3p, are enriched in EO-derived sEVs, and that miR-148a-3p is capable of regulating breast cancer proliferation. Implications: These findings underscore the importance of sEV-mediated communication in the earlier stages of cancer progression, and suggest that EO-derived sEVs may be one mechanism by which the bone microenvironment suppresses breast cancer cell proliferation.
- 21 May 2021
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 19 (10) , 1763-1777
Open AccessStromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
Bone is a common site of cancer metastasis, including cancers such as breast, prostate, and multiple myeloma. Disseminated tumor cells (DTC) shed from a primary tumor may travel to bone and can survive undetected for years before proliferating to form overt metastatic lesions. This period of time can be defined as metastatic latency. Once in the metastatic microenvironment, DTCs engage in intercellular communication with surrounding stromal cells, which can influence cancer cell survival, proliferation, and ultimately disease progression. The role of the surrounding tumor microenvironment in regulating DTC fate is becoming increasingly recognized. We have previously shown that in the bone microenvironment, osteoblasts are “educated” by interactions with breast cancer cells, and these “educated” osteoblasts (EO) produce soluble factors that regulate cancer cell proliferation. In this study, we provide evidence indicating that EOs produce small extracellular vesicles (sEV) that suppress breast cancer proliferation, in part through regulation of ERK1/2 signaling. In addition, using EdU-incorporation assays and propidium iodide staining we demonstrate that exposure to EO-derived sEVs decreases breast cancer cell entry to S-phase of cell cycle. We also have evidence that particular microRNAs, including miR-148a-3p, are enriched in EO-derived sEVs, and that miR-148a-3p is capable of regulating breast cancer proliferation. Implications: These findings underscore the importance of sEV-mediated communication in the earlier stages of cancer progression, and suggest that EO-derived sEVs may be one mechanism by which the bone microenvironment suppresses breast cancer cell proliferation.
- 1 January 2016
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (1) , 45-58
MECP2Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy
An unbiased genome-scale screen for unmutated genes that drive cancer growth when overexpressed identified methyl cytosine-guanine dinucleotide (CpG) binding protein 2 (MECP2) as a novel oncogene. MECP2 resides in a region of the X-chromosome that is significantly amplified across 18% of cancers, and many cancer cell lines have amplified, overexpressed MECP2 and are dependent on MECP2 expression for growth. MECP2 copy-number gain and RAS family member alterations are mutually exclusive in several cancer types. The MECP2 splicing isoforms activate the major growth factor pathways targeted by activated RAS, the MAPK and PI3K pathways. MECP2 rescued the growth of a KRASG12C-addicted cell line after KRAS downregulation, and activated KRAS rescues the growth of an MECP2-addicted cell line after MECP2 downregulation. MECP2 binding to the epigenetic modification 5-hydroxymethylcytosine is required for efficient transformation. These observations suggest that MECP2 is a commonly amplified oncogene with an unusual epigenetic mode of action. Significance:MECP2 is a commonly amplified oncogene in human malignancies with a unique epigenetic mechanism of action. Cancer Discov; 6(1); 45–58. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1
- 1 January 2016
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (1) , 45-58
MECP2Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy
An unbiased genome-scale screen for unmutated genes that drive cancer growth when overexpressed identified methyl cytosine-guanine dinucleotide (CpG) binding protein 2 (MECP2) as a novel oncogene. MECP2 resides in a region of the X-chromosome that is significantly amplified across 18% of cancers, and many cancer cell lines have amplified, overexpressed MECP2 and are dependent on MECP2 expression for growth. MECP2 copy-number gain and RAS family member alterations are mutually exclusive in several cancer types. The MECP2 splicing isoforms activate the major growth factor pathways targeted by activated RAS, the MAPK and PI3K pathways. MECP2 rescued the growth of a KRASG12C-addicted cell line after KRAS downregulation, and activated KRAS rescues the growth of an MECP2-addicted cell line after MECP2 downregulation. MECP2 binding to the epigenetic modification 5-hydroxymethylcytosine is required for efficient transformation. These observations suggest that MECP2 is a commonly amplified oncogene with an unusual epigenetic mode of action. Significance:MECP2 is a commonly amplified oncogene in human malignancies with a unique epigenetic mechanism of action. Cancer Discov; 6(1); 45–58. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1